1. Considered and approved Unaudited Financial Results for the Quarter and Nine Month ended 31st December, 2025 along with the Limited review report; 2. Appointment of Mr. Ritik Pavecha ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Choksi Laboratories' Board met on 7th February 2026 and approved unaudited financial results for Q3 and nine months ended 31st December 2025. Revenue from operations for the quarter stood at ₹1,082.47 lakhs, slightly down from ₹1,111.71 lakhs in the same quarter last year. However, nine-month revenue grew to ₹3,318.37 lakhs from ₹3,040.56 lakhs, and nine-month net profit rose sharply to ₹93.75 lakhs from ₹60.20 lakhs, aided by an exceptional gain of ₹77.80 lakhs from sale of an office flat. The Board appointed Mr. Ritik Pavecha as a Non-Executive Independent Director and accepted the resignation of Mrs. Meenaxi Patidar as Independent Director. A postal ballot notice was also approved.
The improved nine-month profitability and steady revenue growth are positive for shareholders, though the quarter-on-quarter revenue dip and reliance on a one-time property sale gain warrant attention. The board reshuffle appears routine with a new independent director replacing a resigning one.